Telomir Pharmaceuticals Reports Peer-Reviewed Telomir-Zn Data Supporting Phase 1/2 TNBC Program

Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data demonstrating that its lead candidate, Telomir-Zn, suppresses tumor growth in prostate and triple-negative breast cancer (TNBC) models through selective modulation of intracellular iron and copper. The findings, published in the Journal of Oncology Research and Therapy, provide a scientific foundation for advancing Telomir-Zn toward a planned Phase 1/2 clinical trial in TNBC under the company's active Investigational New Drug (IND) application.

The study revealed that Telomir-Zn inhibits histone demethylases by depleting intracellular iron, selectively killing iron-dependent TNBC cells while sparing normal cells at concentrations more than 50-fold higher. Additionally, the compound reactivated tumor-suppressor genes in a prostate cancer model, indicating a potential epigenetic mechanism of action. In TNBC xenograft models, Telomir-Zn reduced primary tumor size across several cell lines and significantly reduced metastatic dissemination in HCC1806 xenografts. In BT-549 xenografts, combining Telomir-Zn with paclitaxel produced significantly greater tumor reduction than either treatment alone, while MDA-MB-231 xenografts did not respond, highlighting tumor-specific differences in sensitivity.

These results are particularly significant because TNBC is an aggressive and difficult-to-treat form of breast cancer, accounting for approximately 15% of all breast cancer cases. Current treatment options are limited, and there is a high unmet need for novel therapies that can effectively target this disease. The data suggest that Telomir-Zn's unique mechanism of action, which involves modulating metal homeostasis and epigenetic regulation, could offer a new therapeutic approach.

Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. The peer-reviewed publication supports the scientific rationale for this trial and provides evidence of the compound's potential efficacy and safety profile.

"The peer-reviewed data validate our approach and support the advancement of Telomir-Zn into clinical trials," said a company spokesperson. "We are encouraged by the results showing selective killing of cancer cells while sparing normal cells, and we look forward to evaluating Telomir-Zn in patients with TNBC."

The announcement underscores the growing interest in targeting metal homeostasis as a cancer therapy. Iron and copper are essential for cell proliferation, and cancer cells often have altered metal metabolism. By selectively modulating these ions, Telomir-Zn aims to disrupt cancer cell survival while minimizing toxicity to healthy tissues.

For more information, visit the full press release at https://ibn.fm/mv3hn.